Abstract: Clopidogrel is a commonly antiplatelet drug used in clinically, reducing the adenosine diphosphate (ADP)-mediated platelet aggregation by binding to the platelet P2Y12 receptor irreversibly. Although clopidogrel has significant effect, there are obvious individual differences. Learning the factors that may cause clopidogrel individual differences to improve the effect of clopidogrel is an issue that clinicians concerns, thus to reduce adverse cardiovascular events. This paper reviews the impact of genetic polymorphisms to clopidogrel pharmacokinetics and pharmacodynamics, and aims to provide a reference for individual dose of clopidogrel in clinically.